Due to momelotinib’s ability to target TBK1, it was studied in KRAS-mutated NSCLC in combination with the MEK 1/2 inhibitor trametinib [35] and in pancreatic adenocarcinoma in combination with nab-paclitaxel and gemcitabine chemotherapy [38]. This evidence concerns the gene MAP2K1 and pancreatic adenocarcinoma.